On November 25, the Food and Drug Administration (FDA) issued 15
warning letters to companies selling products containing
hemp-derived cannabidiol (CBD) and released a summary of its
approach to the regulation of CBD products.
FDA issued these recent warning letters to companies marketing CBD
products with health benefit claims, including claims that the
product will treat conditions such as cancer, anxiety, pain and
inflammation. Keeping in line with prior warning letters FDA has
issued regarding CBD, FDA asserts that these claims render the
products unapproved new drugs in violation of the Federal Food,
Drug and Cosmetic Act (FDCA).
Further, the warning letters discuss FDA’s view that the
FDCA prohibits the sale of food or dietary supplements containing
CBD. In announcing the warning letters, FDA stated that it cannot
conclude that CBD is generally recognized as safe (GRAS) among
qualified experts for use in human or animal food. The warning
letters also focus on